Xerostomia is a major distressing symptom in Sjőgren's syndrome(SS). Preclinical and clinical
studies have demonstrated an increase in saliva volume following rebamipide administration.We
thus hypothesize that rebamipide may be efficacious in the treatment of dry mouth symptoms
related to Sjőgren's syndrome.We will recruit SS patients in a randomized placebo-controlled
trial for 12 weeks. The main outcome measure that will concern us is patient-assessed
improvement of dry mouth symptoms and increase in salivary secretion Safety and efficacy was
assessed at each visit.
Phase:
N/A
Details
Lead Sponsor:
Faculty of Medicine, University of Alexandria University of Alexandria